Sunnyvale-based Embolx spearheaded the year-long initiative to secure this coverage, aiming to broaden patient access to pressure-generating catheter procedures. By formalizing the billing process for office-based labs, the company expects to streamline logistics and reduce costs for treatments involving primary liver cancer and prostate artery embolization. CEO Michael Allen noted that the new code validates the efficacy of transitioning high-quality interventional care away from traditional hospital environments.

Medical practitioners view the update as a practical development for the field. Dr. Aaron Fischman of Mount Sinai highlighted that the Sniper technology already serves as a clinical staple for improving patient outcomes, and the new billing classification provides the necessary infrastructure to scale these procedures. This shift mirrors a broader trend in interventional oncology, where medical teams increasingly prioritize outpatient settings to balance high-standard care with operational efficiency.